Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant toripalimab with or without chemotherapy after neoadjuvant chemoimmunotherapy and surgery in NSCLC without pCR
ChiCTR2600124206Phase 2Not yet recruiting
- Sponsor
- Chengdu Seventh People's Hospital
- Start
- May 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of toripalimab in non-small cell lung cancer (NSCLC) (2 cohorts), sponsored by Chengdu Seventh People's Hospital. Primary endpoint: 2-year disease-free survival rate. Planned start May 2026; status: not yet recruiting.
02
Drugs
toripalimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600124206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124206.